<DOC>
	<DOC>NCT01907763</DOC>
	<brief_summary>The objective of this study is to assess the efficacy and safety of SOTB07 in asthma patients by observing changes FEV1 (% predicted) as the primary efficacy endpoint after oral administration of SOTB07 200mg, 400mg, placebo for 12 weeks.</brief_summary>
	<brief_title>Study Phase III Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients</brief_title>
	<detailed_description>A 12-week, Multi-center, Randomized, Double blinded, Parallel group, Placebo-controlled study to Assess the Efficacy and Safety of SOTB07 in asthma patients</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>1. Male or eligible female subjects aged 15 years or more 2. A female is eligible if she is of: Nonchild bearing potential (i.e., physiologically incapable of becoming pregnant), including any female who is at least 2 year after post menopausal Child bearing potential and agrees to the acceptable contraceptive methods used consistently and correctly Negative pregnancy test at screening 3. Nonsmoker for at least 1 year, a pack history of ≤ 10 pack years 4. Symptom of persistent asthma, as defined by the National Institute of Health (NIH) 5.50% ≤ FEV1 ≤ 80% predicted at screening visit (withholding inhaled, short acting ßagonist for 6 hours) 6.FEV1 reversibility ≥ 12% and 200 ml at 2030 minutes after inhalation of a short acting ßagonist (Salbutamol 2 puffs; 200㎍) at Visit 1 or within 6 months before Visit 1 7.Capable of withholding salbutamol use for ≥ 6 hours prior to clinic visits 8.Appropriately signed and dated informed consent has been obtained 1. Active upper or lower respiratory tract infection within 3 weeks before visit 1 2. Emergency room treatment for asthma within 1 month or hospitalization for asthma within 3 months before visit 1 3. Any evidence of infectious, oncologic, or other active pulmonary disease obtained by chest radiography within 12 months before visit 1 4. Clinically significant, in the opinion of the investigator, hematological, liver, renal, heart, neurological disease, or other serious disease 5. Hypersensitivity to any β2agonist, sympathomimetic drug, leukotriene receptor antagonist or Sophora tonkinensis Radix Rhizoma 6. Clinically significant and uncontrolled psychiatric disease 7. history of drug or alcohol abuse 8. Inhaled, oral or parenteral corticosteroids within 4 weeks before visit 1 9. Change of Immunotherapy within 6 months before visit 1 10. Administration of the antiasthma agent within 1 week of visit 1 11. Administration of any other medication which may affect the course of asthma, or interact with sympathomimetic amines 12. Participation in study using an experimental medication within 1 month before visit 1 13. Other ineligible subject in the opinion of the investigator</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>SOTB07</keyword>
</DOC>